

Company Overview

Medexus Pharmaceuticals Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Collaboration. Medexus is focused on the therapeutic areas of rheumatology, auto-immune disease, specialty oncology and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate (auto-injector and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.

Medexus to Present at the Spring Investor Summit on March 25th

Mar 23 2020, 1:24 PM EDT

Medexus Provides a Business Update and Outlines Response to COVID-19 Pandemic

Mar 23 2020, 8:30 AM EDT

Medexus Expands its US Product Portfolio by Acquiring the Hematology Asset IXINITY®

Feb 28 2020, 8:59 AM EST

Investor Relations

Crescendo Communications, LLC
David Waldman / Natalya Rudman
T: 212-671-1020
mdp@crescendo-ir.com

Management Team

Ken d'Entremont

Chief Executive Officer and Director

Roland Boivin

Chief Financial Officer

Terri Shoemaker

President, U.S. Operations

Medexus Pharmaceuticals, Inc.

1 Place du Commerce
Suite 225
Verdun, QC H3E 1A2
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.